BS_67Z63A2K
EPN · Posterior Fossa EPN
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- Posterior Fossa EPN
- cancer_type
- EPN
- subtype
- Posterior Fossa EPN
- overall_survival_months
- 16.080000000000002
- os_event
- false
- age_years
- 1.688
- sex
- M
- e1_e2
- E2
- umap1_2d
- -6.599698083
- umap2_2d
- 0.330867849
- umap1_3d
- 1.038922974
- umap2_3d
- 3.719349592
- umap3_3d
- 0.208641545
- dataset
- EPN-CBTN
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- BILE_ACID_METABOLISM+0.380
- HEME_METABOLISM+0.260
- KRAS_SIGNALING_DN+0.230
- PEROXISOME+0.200
- NOTCH_SIGNALING+0.190
- MYOGENESIS+0.160
- SPERMATOGENESIS+0.140
- FATTY_ACID_METABOLISM+0.070
- OXIDATIVE_PHOSPHORYLATION+0.070
- ADIPOGENESIS+0.060
Top 10 suppressed
- TNFA_SIGNALING_VIA_NFKB-0.590
- ALLOGRAFT_REJECTION-0.460
- INTERFERON_ALPHA_RESPONSE-0.460
- ANGIOGENESIS-0.450
- E2F_TARGETS-0.450
- INFLAMMATORY_RESPONSE-0.450
- INTERFERON_GAMMA_RESPONSE-0.440
- APOPTOSIS-0.430
- IL6_JAK_STAT3_SIGNALING-0.430
- MYC_TARGETS_V1-0.410
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_67Z63A2K | Posterior Fossa Ependymoma | — | 0.923 |
| 2 | ERR2278853 | — | — | 0.921 |
| 3 | SJEPD001522_R1.RNA-Seq | EPN | EPN Tumor | 0.902 |
| 4 | BS_T2QPMZCM | low-grade glioma | — | 0.899 |
| 5 | SRR15069618 | — | — | 0.893 |
| 6 | SRR1447693 | GTEX | — | 0.889 |
| 7 | SRR1442885 | GTEX | — | 0.879 |
| 8 | SRR818396 | GTEX | — | 0.877 |
| 9 | SRR1359388 | GTEX | — | 0.877 |
| 10 | TCGA-HD-8224-01A-11R-2403-07 | — | — | 0.872 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| BILE_ACID_METABOLISM | 0.380 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.260 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_DN | 0.230 | Remibrutinib | — uncovered |
| PEROXISOME | 0.200 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.190 | Inavolisib | — uncovered |
| MYOGENESIS | 0.160 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.140 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.070 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.070 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.060 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.020 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.020 | Inavolisib | — uncovered |